BioVersys and Shionogi have entered a research and exclusive licence option agreement for the co-development of new ansamycin ...

BioVersys & Shionogi ink global research collaboration for broad-spectrum NTM clinical candidate: Basel, Switzerland Thursday, July 3, 2025, 10:00 Hrs [IST] BioVersys AG, a multi- ...

Shionogi will pay BioVersys $6.3 million for developing BV500, BioVersys's drug candidate for non-tuberculous mycobacteria.

Swiss biopharma company BioVersys (today announced a research and exclusive license option agreement with the Japanese ...

Basel-based BioVersys stands to receive CHF 5 million upfront under the terms of the deal, which could be worth up to CHF 479 ...

Storied Japanese pharma Shionogi is upping its arsenal in the fight against antibiotic resistance. | Storied Japanese pharma ...

Ad hoc announcement pursuant to Art. 53 LR BASEL, Switzerland, July 02, 2025 (GLOBE NEWSWIRE) -- The Global Research Collaboration is a research and exclusive license option agreement with Shionogi to ...

Our top picks Onwrd Trasher Trash Can, $65 Sea to Summit Trash Dry Sack, $40 Bearvault BV500 Journey Bear Canister, $84 Smelly Proof Heavy Duty Reusable Stand-Up Ziplock Bags (5-Pack), $13 ...

BioVersys AG / Key word (s): Conference BIOVERSYS TO PRESENT BV100 PHASE 2 DATA AT 35TH ESCMID GLOBAL 2025 08.04.2025 / 07:00 CET/CEST Basel, Switzerland. April 08, 2025, 7am CEST. Oral presentation ...

Dr. Glenn Dale, Chief Development Officer of BioVersys: “We are delighted to be offered the opportunity to present eight sets of preclinical and clinical data on BV100 and BV500 at this ...

BioVersys AG (SIX: BIOV), a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections caused by ...